Differential modulation by GTPγS of agonist and inverse agonist binding to h5‐HT1Areceptors revealed by [3H]‐WAY100,635
- 29 January 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (2) , 518-524
Abstract
The interaction of serotonergic ligands at human (h) 5‐HT1Areceptors expressed in Chinese hamster ovary cells was examined with the selective ‘neutral’ 5‐HT1Aantagonist [3H]‐WAY100,635. Its binding was saturable (KD=0.056 nM) with a Bmax(3.65 pmol mg−1) significantly higher than that of two other selective 5‐HT1Aradioligands: the partial agonist, [3H]‐S15535 (2.77 pmol mg−1) and the agonist, [3H]‐8‐OH‐DPAT (2.02 pmol mg−1). The influence of GTPγS (100 μM) on the binding affinity of 15 serotonergic agonists, partial agonists, antagonists and inverse agonists was investigated in competition binding experiments with [3H]‐WAY100,635. Agonists, including 5‐HT, 8‐OH‐DPAT and buspirone, displayed biphasic isotherms which shifted to the right in the presence of GTPγS. In contrast, isotherms of theinverseagonists, methiothepin, (+)butaclamol and spiperone, were shifted to the left in the presence of GTPγS. Unlabelled WAY100,635 was the only ligand that was unaffected by GTPγS, consistent with ‘neutral’ antagonist properties. The magnitude of affinity changes induced by GTPγS for 13 ligands was highly correlated (r=0.98) with their efficacy (positive and negative) previously determined by [35S]GTPγS binding. In contrast, the napthylpiperazine derivative and high efficacy agonist, S14506, displayed only a modest GTPγS shift, in accordance with previous indications of ‘atypical’ binding properties of this ligand. A further full agonist, S14671, which is chemically closely‐related to S14506, also displayed a minimal GTPγS shift, underpinning this observation. In conclusion, [3H]‐WAY100,635 constitutes a useful neutral antagonist radioligand for the characterization of drug actions at h5‐HT1Areceptors. GTPγS‐induced affinity changes of agonist and inverse agonist competition isotherms generally correlate well with ligand efficacy, with the notable exception of two chemically‐similar agents, S14506 and S14671, which are efficacious agonists, yet relatively insensitive to h5‐HT1Areceptor/G‐protein coupling changes. British Journal of Pharmacology(2001)132, 518–524; doi:10.1038/sj.bjp.0703832Keywords
This publication has 36 references indexed in Scilit:
- 5‐HT1A receptor agonist‐antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systemsBritish Journal of Pharmacology, 2000
- Agonist high and low affinity state ratios predict drug intrinsic activity and a revised Ternary complex mechanism at serotonin 5-HT2A and 5-HT2C receptorsSynapse, 1999
- Agonist and Antagonist Actions of (-)Pindolol at Recombinant, Human Serotonin1A (5-HT1A) ReceptorsNeuropsychopharmacology, 1998
- Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptorsJournal of Neural Transmission, 1997
- Inhibition of the constitutive activity of human 5‐HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635British Journal of Pharmacology, 1997
- Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]way-100635Life Sciences, 1997
- Development of 5-HT1A receptor antagonistsBehavioural Brain Research, 1995
- Characterisation of Recombinant Serotonin 5‐HT1A Receptors Expressed in Chinese Hamster Ovary Cells: The Agonist [3H]Lisuride Labels Free Receptor and Receptor Coupled to G ProteinJournal of Neurochemistry, 1995
- The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranesEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- The 5-HT1A receptor antagonist (S)-UH-301 blocks the (R)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the ratJournal of Neural Transmission, 1994